Previous 10 | Next 10 |
Amneal Pharmaceuticals (NYSE: AMRX ) is up 6% premarket after the launch of its generic version of Pfizer's Lyrica (pregabalin capsules) 25 mg, 50, 75, 100, 150, 200, 225 and 300 mg. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...
- Company has launched 21 generic products so far in 2019 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval for, and launched, its generic version of Lyrica ® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg a...
July 18, 2019 Palm Beach, FL –July 18, 2019 – Acute myeloid leukemia (AML) is a cancer that is rarely seen before age 45 with the average age of onset around 65. It is the most common of the four major types of leukemia. Without treatment, AML is often deadly wi...
Insider buying is usually a bullish sign while insider selling is seen as bearish. For instance, there were a lot of executive options exercised with some of them sold at $13.44 on May 7th on Amneal Pharmaceuticals, Inc. ( AMRX ) a couple of days before the company was to release Q1 results: ...
Spectrum Pharmaceuticals (NASDAQ: SPPI ) initiated with Buy rating and $18 (114% upside) price target at B. Riley FBR. More news on: Spectrum Pharmaceuticals, Inc., Immunic, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Gainers: Vislink Technologies (NASDAQ: VISL ) +316% . Attis Industries (NASDAQ: ATIS ) +32% . Valeritas Holdings (NASDAQ: VLRX ) +27% . Harmonic (NASDAQ: HLIT ) +26% . Akoustis Technologies (NASDAQ: AKTS ) +21% . SMART Global Holdings (NASDAQ: SGH ) +21% . ContraVir Pharmaceuti...
Camber Energy (NYSEMKT: CEI ) -21% . More news on: Camber Energy, Inc., Amneal Pharmaceuticals, Inc., Yuma Energy, Inc., Stocks on the move, Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ) has designed a restructuring plan to reduce cost base, further right size its organization and optimize manufacturing infrastructure. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
‒ Plan expected to reduce costs by approximately $50 million annually ‒ ‒ Reduces Full Year 2019 Adjusted EBITDA Guidance ‒ Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced a comprehensive restructuring plan designed to reduce its cost base, furthe...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...